The prognosis of oesophageal cancer is usually dismal. Surgery is potentially curative in only a small subset of patients (Altorki and Skinner, 1990) . Oesophageal resection is considered major surgery, which includes substantial morbidity and mortality. Although post-operative mortality has decreased over the last years and is acceptably low (5%) in some centres, resection as a palliative measure is not widely accepted in clinical practice. In the case of unresectable oesophageal cancer or advanced locoregional disease, radical radiotherapy may offer adequate palliation (Beatty et al., 1979) , although overall prognosis is poor and progression may be apparent even during irradiation in up to 20% of patients (Wara et al., 1976) . Since the review of the literature on the role of radiotherapy by Earlam and Cunho-Melo (1980) , radiation techniques have changed, especially after brachytherapy was in favour again when remote control techniques became available, as described by Rowland and Pagliero (1985) ; followed by others (Petrovich et al., 1991; Smalley et al., 1994) . In most studies (Caspers et al., 1993; Flores et al., 1989; Gaspar, 1994; Hishikawa et al., 1991; Hyden et al., 1988; Sur et al., 1992) , intracavitary irradiation has been used as a booster following external radiotherapy, which has the advantage of delivering a high dose to a small tumour volume.
As dysphagia is the main symptom in oesophageal cancer leading to weight loss and deterioration of the general condition, we applied brachytherapy before EBRT to induce rapid tumour reduction and subsequent relief of dysphagia. Aiming at optimal tumour regression and improved quality of life, at the cost of minimal side-effects, we based our regimen on the two largest series in the literature: that of Flores et al. (1989) , who combined a short course of EBRT (40 Gy over 3 weeks) with medium dose rate brachytherapy (15 Gy), and the wide experience of Hishikawa et al. (1991) using high dose rate (2 x 6 Gy) in addition to EBRT (60 Gy over 6 weeks). With regard to dysphagia and the generally short life expectancy, we applied 10 Gy HDR brachytherapy before a short duration radiotherapy scheme, 40 Gy over 3 weeks EBRT. When this appeared to be too toxic in a pilot study, in nine out of 15 patients severe late side-effects, e.g. ulceration, necrosis and fistula formation (Taal et 
Evaluation
Evaluation of symptoms and signs such as dysphagia, pain and use of medication, as well as tumour measurements were performed 4-6 weeks after the end of radiotherapy and at regular intervals of 6-8 weeks thereafter. Endoscopy was the evaluation method of choice. In case of patient's refusal, only a barium swallow was performed, combined with a CT scan, when there was suggestion of tumour recurrence. Responses were assessed according to WHO criteria: a complete response (CR) defined as no macroscopic tumour; near complete remission was defined as a residue of only a few mm in diameter detected by endoscopy; a partial remission (PR) occurred when at least 50% tumour reduction was found; no change (NC) was found in case of variation within 50% regression and 25% progression of the tumour; progressive disease was recorded when an increase of at least 25% was present. Biopsies were not routinely taken to document remission. The duration of response was measured from the start of treatment until the first sign of recurrence at endoscopy. For grading of toxicity the WHO recommendations were used. In addition, specific endoscopic patterns were interpreted as acute radiation effect in the case of superficial erosions with a fibrin lining and disappearance of tumour, or chronic radiation ulceration as described by Yang et al. (1990) , including a demarcation line of ulceration and intact opposite wall of the oesophagus.
Statistics
Survival time was calculated from the start of radiotherapy to the time of death or the last follow-up. Follow-up was until date of death. Median follow-up of patients alive (n=20) at the moment of the evaluation of the present study was 6 months (range 2-31 months).
Results
Among the 74 patients, 52 were men (70%) and a minority of 22 (30%) women; median age was 67 years, with a wide range of 49-91 years. Pretreatment characteristics, as summarised in Table II , revealed an almost equal number of squamous cell and adenocarcinomas, which can be expected based on a localisation mostly in the distal (48 or 65%) and middle (23 or 31%) part of the oesophagus. According to the 1987 UICC TNM staging (Table I) , the majority of patients (51 or 69%) were in an advanced stage (III or IV). Although 23 patients were in stage II, indicating relatively limited tumour burden, other parameters were considered unfavourable, explaining the preference for radiotherapy instead of surgery, e.g. poor condition (n = 7), age over 80 years (n =7) with moderate condition, a very long (> 10 cm) tumour (n = 5), or cardiopulmonary contraindication for surgery (n = 4). Explorative surgery, usually laparotomy, performed in 30 patients, revealed unexpected invasion into the surrounding organs (T4) in ten patients or multiple malignant lymph nodes at the coeliac axis, which are considered as metastatic disease (Ml) in 20 patients.
Endoscopic dilatation within 4 weeks before the start of radiotherapy for tumour measurement and palliation of dysphagia was necessary in 24 patients. Treatment results in terms of symptoms and signs (Table III) b Figure 1 The barium meal in a 74-year-old woman who could take nothing but fluids, leading to weight loss, revealed an obstructing tumour of 6cm in length (a). Following radiotherapy an impressive improvement in dysphagia, owing to tumour reduction at barium meal with some stenosis (b); complete remission was confirmed by endoscopy. patients who could take an almost normal diet increased from 12 (16%) to 36 (49%). In only 15% of the patients dysphagia remained a major problem as they could eat nothing but fluids, compared with 35 patients (47%) before treatment. Along with improvement of dysphagia, no further weight loss occurred in 39 patients, and in five cases even some gain in weight was assessed during the weeks of external radiotherapy.
Retrosternal pain at presentation occurred either at eating (n = 5), during obstruction (n = 8), or was continuous (n = 12). Pain improved in 12 of those 25 patients (48%), but occasionally became more prominent (n =3). In nine other patients pain appeared after treatment. Thus, the overall incidence of pain remained similar.
Although most oesophageal tumours were friable and easily bleeding at endoscopy, haematemesis and melaena were rare conditions at presentation (3 or 4%). Also during follow-up it was seen in only six patients (median interval 17 months), all with tumour recurrence. In four of them it was a terminal and fatal event.
Objective tumour response (Table IV) , as evaluated by endoscopy and/or barium swallow, was present in 59 patients (80%): in 21 complete ( Figure 1) ; and 12 near complete with only a small nodule of a few mm at endoscopy ( Figure 2) ; in the other 26 the criteria of partial response with more than 50% tumour reduction were met. In squamous cell carcinoma the overall response was not different from adenocarcinoma (Table IV) . As 20 patients were still alive at the time of the analysis, duration of response is not yet fully known. In the 54 patients who had died at the time of analysis, the median duration of response was 6 months (range 2-16 months). Additional treatment directly following radiotherapy, in case of failure, was required in only two cases, in whom a self-expandable stent was inserted. Local recurrence was found in 40 patients during follow-up investigations at regular intervals of 6 weeks according to the trial protocol; this might explain why recurrence was usually found before dysphagia recurred. The need for an endoprosthesis was, therefore, at a later time, median 7-8 months.
At the time of the analysis most patients (n= 54 or 72%) had died. As shown in the survival curve (Figure 3 ), the overall median survival was 9 months (range 2-43 months). No adverse effects related to brachytherapy were found. Side-effects (Table V) were either acute (n= 32 or 42%) at the end of external radiotherapy, or late with a median interval of 4 months (n = 20 or 27%). Acute oesophagitis, as observed at endoscopy, was mild and short-lasting (1 -2 weeks), leading to some retrosternal burning sensation, but without interfering with eating and without the need for analgesics. Delayed side-effects (> 2 months following radiotherapy) tended to be more severe, among which fistula formation was the most serious. This serious condition of fistula formation, usually diagnosed at radiography, was present in six patients with squamous cell carcinoma in the middle of the Time from treatment (months) Figure 2 A tiny nodule at endoscopy as the result of impressive tumour reduction in a 66-year-old man with adenocarcinoma of 7 cm; near complete remission after radiotherapy. Progression with the need of an endoprosthesis after 24 months and at 31 months the patient is still alive and well. Figure 3 The overall survival in patients with inoperable oesophageal cancer, following an irradiation scheme of HDR brachytherapy and EBRT. Median survival is 9 months. (Bown, 1991) . The new generation of coated self-expandable stents are especially indicated in case of oesophago-bronchial fistula (Taal et al., 1995a) . However, for patients with locally advanced disease, but still in fair condition, it is widely accepted to apply radiotherapy to achieve adequate palliation. Various schemes of irradiation are being used. Regimens to achieve long-term palliation or even cure are usually referred to as radical radiotherapy in the literature, and consist of doses of 50-60 Gy delivered in 5-6 weeks. Nevertheless, figures of 5 year survival are only 6% as mentioned in the well-known review of Earlam and Cunho-Melo (1980) . Even in several other series, up to 85% of patients still die from persistent or recurrent primary tumour (Beatty et al., 1979; Smalley et al., 1994) . Therefore, improvement in results is greatly needed. Intraluminal radiotherapy (brachytherapy) is not new, but recent technical advances allowing HDR brachytherapy may offer several advantages over the conventional technique of external irradiation alone: better local control, reduction of treatment time and, when given before external radiotherapy, rapid improvement of dysphagia. Several studies (Hyden et al., 1988; Petrovich et al., 1991; Sur et al., 1992) (Flores et al., 1989; Hishikawa et al., 1991) .
Most studies (Table VI) (Caspers et al., 1993; Hyden et al., 1988) (1995) . However, responses are usually of shorter duration (4 months) compared with the combined irradiation schemes (8-9 months). Therefore, in our institute brachytherapy alone is especially recommended in patients with a short life expectancy.
In conclusion, upfront HDR brachytherapy resulted in Radiotherapy in oesophageal cancer BG Taal et al 1457 rapid improvement of dysphagia and, when combined with a condensed external radiation scheme, adequate long-term palliation was achieved in both squamous and adenocarcinoma alike. Although local response was excellent and sideeffects acceptable, eventually patients suffered from local recurrent disease, which was rapidly fatal in 59%. Thus, there is still a major need for improvement of long-term results, which might be achieved by a higher dose of external radiotherapy, as used by Hishikawa et al. (1991) , or by combining radiotherapy with multiagent full dose chemotherapy. A review of studies (Rich and Ajaui, 1994) reporting the results of combined modality, showed a modest benefit compared with radiotherapy alone, e.g. an increase in median survival from 8 to 12 months at the cost of increased toxicity (Herskovic et al., 1992) or some long-term survivors (Coia et al., 1991) . Another option, using a low-dose chemotherapy scheme as radiosensitiser, might be of benefit. Such an approach has been shown to improve local control, and eventually survival, in non-small-cell lung cancer (Schaake-Koning et al., 1992) . Combinations of radiotherapy schemes, including brachytherapy to induce rapid relief of dysphagia, with chemotherapy to achieve long-term survival, will be the subject of a future trial in the Netherlands.
